Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma

Detalles Bibliográficos
Autores principales: Puzanov, Igor, Milhem, Mohammed, Andtbacka, Robert, Minor, David, Hamid, Omid, Li, Ai, VanderWalde, Ari, Kaufman, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991001/
http://dx.doi.org/10.1186/2051-1426-1-S1-P84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991001/
http://dx.doi.org/10.1186/2051-1426-1-S1-P84

Ejemplares similares